EIN 01-0741733

International Partnership for Microbicides (IPM)

IRS 501(c) type
Num. employees
Year formed
Most recent tax filings
IPM's mission is to prevent HIV transmission by accelerating the development and availability of safe and effective microbicides for use by women in developing countries.
Total revenues
Total expenses
Total assets
Num. employees

Program areas at IPM

Product development: The product development (PD) division leads non-clinical, formulation, manufacturing, chemistry manufacturing and controls (CMC), analytical, and material planning and supply activities for IPM's products. This division is responsible for product supply and associated activities to support clinical trials (including manufacturing, packaging, labeling, distribution, stability) as well as the post-use testing of dapivirine rings to support adherence assessments during trials. In 2020, PD's efforts included conducting CMC gap-filling activities to address feedback received from regulatory agencies, including the questions received from the EMA as part of the review process of the monthly dapivirine ring regulatory dossier. Following the Positive Scientific Opinion from the EMA for the DVR, the PD team began preparations for commercial manufacturing of the DVR. This included completing capacity planning with critical vendors such as IPM's DVR product manufacturing partner, IPM's dapivirine drug substance manufacturing partners and IPM's silicone manufacturing partner. Subsequently, commercial manufacturing of DVRs began in Q4 2020. Additionally, the product development team is supporting organizational efforts to negotiate contracts with global health supply procurement agencies for procurement and distribution of the DVR once in-country regulatory approvals are received. Further to this, the PD team continued development the three-month dapivirine ring and the dapivirine-contraceptive ring.
Clinical Affairs: IPM's clinical affairs department is responsible for quality control and compliance, medical safety, clinical operations, biometrics, public affairs, community public affairs and socio-behavioral sciences for the clinical trials conducted on IPM's products. Key activities in 2020 included: - Clinical Trials of the monthly dapivirine vaginal ring (DVR) IPM's worked with clinical trial partner, the United States (US) National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN) on the following clinical trials of the DVR: o MTN-034 (REACH): A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population o MTN-042 (DELIVER): Phase 3b, Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring (VR) and Oral TRUVADA Use in Pregnancy o MTN-043 (B-PROTECTED): Phase 3B, Open-label, Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA in Breastfeeding Mother-Infant Pairs Further to this, the Clinical Affairs team supported the Regulatory Affairs team in development and completion of the clinical modules of the DVR dossiers submitted to regulatory authorities to support the regulatory approval of the DVR. Following receipt of the European Medicines Agency (EMA) Positive Scientific Opinion for the DVR, the Clinical Affairs team supported the Regulatory Affairs team with ongoing post-authorization commitments to the EMA. - Clinical trial of IPM's three-month dapivirine ring Building on the promise of IPM's monthly dapivirine ring, IPM developed the three-month dapivirine ring, which is designed to increase convenience and reduce annual costs as compared to the monthly dapivirine ring. The phase I trial, which was conducted by the MTN in collaboration with IPM, will inform the design of future clinical studies and a possible regulatory strategy for this product. The Clinical Affairs team supports the data analysis and clinical study report efforts. - Clinical trials of the dapivirine-contraceptive vaginal ring, a multipurpose prevention technology (MPT) The three-month dapivirine-contraceptive ring is designed to provide slow and simultaneous release of both the antiretroviral (ARV) drug dapivirine to prevent HIV and the contraceptive hormone levonorgestrel to prevent unintended pregnancy. A second phase I clinical trial of the MPT ring was conducted by the Contraceptive Clinical Trials Network (CCTN) from Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) in collaboration with the MTN. The trial began in July 2018 and participant visits completed in August 2019. The Clinical Affairs team supports the data analysis and clinical study report efforts.
Regulatory Affairs and Quality Assurance: IPM's regulatory affairs team oversees the monthly dapivirine ring regulatory process, providing leadership in dossier preparation and filings in Europe, the United States, South Africa and other target African countries, where IPM is planning market introduction of the ring. This division also supports all regulatory efforts for other IPM products on the product development pathway; this support includes submission and maintenance of investigational new drug (IND) documentation and conducting regulatory agency interactions related to new protocols for upcoming clinical trials. Importantly, in 2020, the Regulatory Affairs team was responsible for managing the final stages of the EMA regulatory review process for the DVR, resulting in the DVR receiving a positive scientific opinion from the EMA for use by cisgender women ages 18 and older in developing countries, World Health Organization (WHO) prequalification (PQ) and a recommendation from the WHO as an additional HIV prevention choice for women as part of combination prevention. The monthly DVR is now under regulatory review in African countries. In partnership with the regulatory affairs team, the quality assurance (QA) team ensures IPM's product development and clinical studies are conducted in compliance with all applicable drug and safety laws. Audits are conducted during the conduct of clinical trials to provide assurance of protocol compliance, and compliance with international conference on harmonization of technical requirements for registration of pharmaceuticals for human use (ICH) guidelines, good clinical practices (GCP), and all applicable regulations. Vendor audits are also conducted where IPM's clinical, preclinical, or CMC work is being conducted.

Who funds International Partnership for Microbicides (IPM)

Grants from foundations and other nonprofits
Bill & Melinda Gates FoundationHiv$2,000,000
Federal funding details
Federal agencyProgram nameAmount
U. S. Agency for International DevelopmentUSAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS$7,883,397

Personnel at IPM

Zeda F. RosenbergFounder and Chief Executive Officer$522,944
Michael GoldrichPresident and Chief Operations Officer$482,713
Mike GoldrichPresident and Chief Operating Officer
Willem KrielChief Operations Officer , South Africa / Vice President , Clinical Affairs
Kathy FlynnChief Financial Officer
...and 20 more key personnel

Financials for IPM

RevenuesFYE 12/2020
Total grants, contributions, etc.$20,127,462
Program services$0
Investment income and dividends$34,631
Tax-exempt bond proceeds$0
Royalty revenue$0
Net rental income$0
Net gain from sale of non-inventory assets$2,691
Net income from fundraising events$0
Net income from gaming activities$0
Net income from sales of inventory$0
Miscellaneous revenues$0
Total revenues$20,164,784

Form 990s for IPM

Fiscal year endingDate received by IRSFormPDF link
2020-122021-08-16990View PDF
2019-122021-02-19990View PDF
2018-122019-12-20990View PDF
2017-122018-10-16990View PDF
2016-122017-10-19990View PDF
...and 7 more Form 990s
Data update history
July 4, 2022
Updated personnel
Identified 3 new personnel
June 12, 2022
Posted financials
Added Form 990 for fiscal year 2020
June 2, 2022
Used new vendors
Identified 2 new vendors, including , and
September 22, 2021
Received grants
Identified 1 new grant, including a grant for $2,000,000 from Bill & Melinda Gates Foundation
August 22, 2021
Posted financials
Added Form 990 for fiscal year 2019
Nonprofit Types
Social advocacy organizationsInternational-focused organizationsCharities
HealthDiseases and disordersHIV / AIDSForeign affairsInternational developmentPublic policy
Political advocacyLobbyingOperates internationallyReceives government fundingTax deductible donations
General information
8405 Colesville Rd Suite 600
Silver Spring, MD 20910
Metro area
Washington-Arlington-Alexandria, DC-VA-MD-WV
Montgomery County, MD
Website URL
Facebook page
Twitter profile
IRS details
Fiscal year end
Taxreturn type
Form 990
Year formed
Eligible to receive tax-deductible contributions (Pub 78)
NTEE code, primary
Q30: International Development, Relief Services
NAICS code, primary
813319: Social Advocacy Organizations
Parent/child status
Free account sign-up

Want updates when IPM has new information, or want to find more organizations like International Partnership for Microbicides (IPM)?

Create free Cause IQ account